Search research articles
Contact Us
Filters
Showing results (151-160 of 163) with videos related to
Page
of 17
Sort By:
The Lancet. Oncology
|
September 18, 2024
Sequential [<sup>177</sup>Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
Arun A Azad, Mathias Bressel, Hsiang Tan, et al.
Journal of Medicinal Chemistry
|
July 2, 2013
2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways
Andrew J Kassick, Jinlong Jiang, Jaime Bunda, et al.
Kidney International
|
March 22, 2024
Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns
Adeera Levin, Sofia B Ahmed, Juan Jesus Carrero, et al.
Annals of Internal Medicine
|
March 10, 2025
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline
Magdalena Madero, Adeera Levin, Sofia B Ahmed, et al.
The Lancet. Oncology
|
December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Michael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Lancet (London, England)
|
February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
The Lancet. Oncology
|
April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology
|
February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 10, 2023
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06
Nathaniel Barry, Roslyn J Francis, Martin A Ebert, et al.
Kidney International Reports
|
August 15, 2025
Kidney Disease: Improving Global Outcomes Summit Recommendations on Implementation of Diabetes Management in CKD: From Primary to Data-Driven Collaborative Care
Philip Kam-Tao Li, Michael Cheung, Kai-Ming Chow, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 163) with videos related to
Sort By:
Page
of 17
The Lancet. Oncology
|
September 18, 2024
Sequential [<sup>177</sup>Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
Arun A Azad, Mathias Bressel, Hsiang Tan, et al.
Journal of Medicinal Chemistry
|
July 2, 2013
2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways
Andrew J Kassick, Jinlong Jiang, Jaime Bunda, et al.
Kidney International
|
March 22, 2024
Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns
Adeera Levin, Sofia B Ahmed, Juan Jesus Carrero, et al.
Annals of Internal Medicine
|
March 10, 2025
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline
Magdalena Madero, Adeera Levin, Sofia B Ahmed, et al.
The Lancet. Oncology
|
December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Michael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Lancet (London, England)
|
February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
The Lancet. Oncology
|
April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology
|
February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 10, 2023
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06
Nathaniel Barry, Roslyn J Francis, Martin A Ebert, et al.
Kidney International Reports
|
August 15, 2025
Kidney Disease: Improving Global Outcomes Summit Recommendations on Implementation of Diabetes Management in CKD: From Primary to Data-Driven Collaborative Care
Philip Kam-Tao Li, Michael Cheung, Kai-Ming Chow, et al.
Page
of 17